Document Detail


Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.
MedLine Citation:
PMID:  19165664     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To compare donor and recipient outcome after inducing the final oocyte maturation with hCG or GnRH agonist in GnRH-antagonist treated oocyte donation (OD) cycles.
METHODS: Two-hundred fifty-seven oocyte donors were enrolled to participate in a clinical trial in a private fertility centre. After stimulation with 225 IU rFSH and Cetrorelix 0.25 mg/day, 212 oocyte donors were randomised with sealed envelopes for triggering with recombinant hCG (Ovitrelle 250 microgr, n = 106) or a GnRH agonist (triptorelin 0.2 mg, n = 106).
RESULTS: The number of retrieved COCs (12 +/- 6.3 vs 11.4 +/- 6.4), mature oocytes (8 +/- 4.6 vs 7.5 +/- 4.1), the proportion of mature oocytes (67.2 +/- 20.4% vs 67.1 +/- 20.9%) and fertilisation rates (67.8 +/- 23.5% vs 71.1 +/- 22.1%) were comparable. Clinical, ongoing pregnancy and live birth rates were not statistically different in the corresponding recipient groups. Nine cases of mild and one case of severe OHSS occurred in hCG group, whereas no cases were detected in GnRH agonist group.
CONCLUSIONS: The findings of our RCT suggest that donor and recipient outcome are comparable in OD cycles triggered with hCG or a GnRH agonist. Furthermore, the risk of OHSS seems to be reduced considerably, therefore the combination of a GnRH antagonist protocol with GnRH agonist triggering constitutes a safe treatment option for egg-donors.
Authors:
Anna Galindo; Daniel Bodri; Juan José Guillén; Marta Colodrón; Valérie Vernaeve; Oriol Coll
Related Documents :
7789544 - Pregnancy in women 50 or more years of age: outcomes of 22 consecutively established pr...
8690114 - Age does not affect uterine resistance to vascular flow in patients undergoing oocyte d...
16466394 - Sex reversal in medaka treated in vitro with 17alpha-methyldihydrotestosterone during o...
18477574 - Freezing within 2 h from oocyte retrieval increases the efficiency of human oocyte cryo...
17018504 - Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
21277024 - The role of the nod-like receptor family in trophoblast innate immune responses.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology     Volume:  25     ISSN:  1473-0766     ISO Abbreviation:  Gynecol. Endocrinol.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-23     Completed Date:  2009-04-02     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8807913     Medline TA:  Gynecol Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  60-6     Citation Subset:  IM    
Affiliation:
Clinica EUGIN, calle Entença 293-295, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Chorionic Gonadotropin / therapeutic use*
Female
Gonadotropin-Releasing Hormone / agonists*,  analogs & derivatives,  antagonists & inhibitors*,  therapeutic use
Hormone Antagonists / therapeutic use
Humans
Luteolytic Agents / therapeutic use*
Male
Oocyte Donation / methods*
Ovulation Induction / methods*
Pregnancy
Pregnancy Rate
Recombinant Proteins / therapeutic use
Sperm Injections, Intracytoplasmic
Treatment Outcome
Triptorelin Pamoate / therapeutic use
Young Adult
Chemical
Reg. No./Substance:
0/Chorionic Gonadotropin; 0/Hormone Antagonists; 0/Luteolytic Agents; 0/Recombinant Proteins; 33515-09-2/Gonadotropin-Releasing Hormone; 57773-63-4/Triptorelin Pamoate; OON1HFZ4BA/cetrorelix

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low-dose human chorionic gonadotropin during the proliferative phase may adversely affect endometria...
Next Document:  In vitro fertilization is associated with an increased risk for preeclampsia.